|
11 May 2018 |
Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent
|
|
10 May 2018 |
VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine
|
|
08 May 2018 |
Neon Therapeutics Announces First Patient Treated in Clinical Trial Evaluating Personal Cancer Vaccine NEO-PV-01 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy
|
|
02 May 2018 |
Targovax announces early signal of efficacy in ONCOS-102 trial in mesothelioma
|
|
30 Apr 2018 |
Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009
|
|
27 Apr 2018 |
Aduro Biotech Presents Early Observations From its Personalized Neoantigen-based pLADD Therapy Clinical Study at European Neoantigen Summit
|
|
25 Apr 2018 |
Boston Biomedical Inc. Initiates Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*)
|
|
23 Apr 2018 |
Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
|
|
20 Apr 2018 |
Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives
|
|
19 Apr 2018 |
NovaDigm Therapeutics Announces Initiation of Phase 2a Clinical Trial of NDV-3A in Staphylococcus aureus
|
|
19 Apr 2018 |
Qu Biologics Begins Phase 2 Clinical Trial in Crohn’s Disease
|
|
18 Apr 2018 |
Elios Therapeutics Presents Initial Phase 2b Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine for the Treatment of Melanoma, at the American Association for Cancer Research (AACR) 2018 Annual Meeting
|
|
17 Apr 2018 |
Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine
|
|
16 Apr 2018 |
Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors
|
|
15 Apr 2018 |
Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European Countries
|
|
15 Apr 2018 |
Personalized tumor vaccine shows promise in pilot trial
|
|
12 Apr 2018 |
Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
|
|
05 Apr 2018 |
Vivaldi Biosciences Presents Data at the World Vaccine Congress Demonstrating Potential of deltaFLU as Universal Influenza Vaccine
|
|
02 Apr 2018 |
SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Herceptin® in HER2 1+/2+ Breast Cancer Patients
|
|
28 Mar 2018 |
Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL
|
|
27 Mar 2018 |
Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection
|
|
20 Mar 2018 |
AJ Vaccines successfully completes two phase III trials of its new low-dose IPV-Al vaccine
|
|
19 Mar 2018 |
SELLAS Life Sciences’ Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting
|
|
19 Mar 2018 |
Valneva Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15
|
|
16 Mar 2018 |
OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
|
